DSIP
Also known as delta sleep-inducing peptide, delta sleep inducing peptide, delta-sleep-inducing peptide, emideltide, emideltide acetate, DSIP peptide, WAGGDASGE, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
A nine-amino-acid peptide named for an EEG effect in rabbits. Small 1980s human sleep studies were mixed, and independent ones found little or no benefit.
DSIP has been tested in people only in small controlled studies from the 1980s and 1990s, mostly from the group that discovered it, and no registered or ongoing trial was found in a ClinicalTrials.gov search. The independent controlled studies found little or no effect: one in 16 people with chronic insomnia called the effects weak (source), another found slow-wave sleep "not modified" (source), and a randomised study in 24 anaesthetised patients found a reduction in delta rhythm at the lowest dose (source). In its July 2026 briefing, FDA found no data supporting its effectiveness for chronic insomnia, narcolepsy or opioid withdrawal by the nominated route and recommended against adding it to the 503A compounding list (source).
What it is
DSIP, delta sleep-inducing peptide, is a chain of nine amino acids, WAGGDASGE (source). FDA's substance registry names it emideltide. Its formula is C35H48N10O15 and its molecular weight 848.8 (source). A related substance, N-acetyl emideltide, is registered separately and is not covered by this page.
The name describes how it was first characterised. In 1977 Schoenenberger and Monnier reported that the peptide, infused into the brain ventricles of rabbits, enhanced delta and spindle patterns on the EEG, the slow brain waves of deep sleep (source). It is not a demonstrated effect in people.
No gene, precursor protein or receptor for DSIP has been identified, according to a 2006 review (source). A 2011 database analysis proposed related proteins only as putative precursors (source).
Sleep in people
The positive reports come mainly from Schneider-Helmert and colleagues, working with a co-discoverer of the peptide. In 14 middle-aged people with chronic insomnia, comparing DSIP and placebo nights in the same people, they report "substantially improved night sleep" by polysomnography, without figures in the abstract (source).
The 59% figure that circulates online comes from 6 healthy volunteers. Sleep rose by a median of 59% over placebo within a 130-minute window after a morning infusion (source). It is not a measure of night-time sleep or of insomnia.
Withdrawal and other uses
Two inpatient series in alcohol and opiate withdrawal, of 67 and 107 patients, report most evaluable patients improved (source, source).
In animals
The rabbit finding was not consistently repeated. In rats DSIP did not increase sleep in two studies (source, source). In cats one study found more slow-wave sleep (source) and another found less sleep (source).
Regulatory position
FDA lists emideltide among bulk substances nominated for compounding but withdrawn, and says it lacks the information to know whether it would harm people (source). Its advisory committee nonetheless considered emideltide on 24 July 2026 for opioid withdrawal, chronic insomnia and narcolepsy (source); the sources found do not explain why. FDA's briefing states that emideltide is not a registered drug in any country it searched (source). It has no entry in the May 2026 503A categories list (source). Press and legal reports, which are second hand, say the committee voted against adding emideltide to the list, 6 in favour and 7 against with one abstention; FDA had posted no vote record by 6 November 2026 (source, source). HHS's October 2026 enforcement policy on compounded peptides names six substances and emideltide is not one of them (source).
What the research shows
Each statement below is labelled with the strongest kind of study supporting it, and links to that study.
- Human randomised trialContradictory / Low confidence
In 24 women under general anaesthesia, a randomised saline-controlled study measured by EEG found DSIP, at the lowest of three doses, reduced delta rhythm and appeared to lighten anaesthetic depth.
Pomfrett and colleagues (2009, Manchester) randomly assigned 12 of 24 female surgical patients to saline and 12 to DSIP. Measured by bispectral index, EEG and heart rate variability, DSIP "significantly increased heart rate, decreased HRV and, paradoxically, significantly reduced delta rhythm", findings reported at the lowest dose (25 nmol/kg) during isoflurane anaesthesia, with the 12 DSIP patients split across three doses. The authors say it probably lightened the depth of anaesthesia.
Tested in humans under randomised, controlled conditions.
- Not a sleep study, and 12 patients received DSIP across three doses. Blinding is not stated. Abstract only.
- It is the most recent randomised human study found, and its delta result runs against the peptide's name.
- Human randomised trialContradictory / Very low confidence
In healthy volunteers, placebo-controlled hormone studies conflict: two report lower ACTH after DSIP (11 and 8 men) and one reports no effect on ACTH or cortisol (5 men per condition); in 8 healthy women DSIP did not change growth hormone or prolactin.
Bjartell and colleagues (1989), a randomised double-blind crossover in 11 healthy men, found plasma ACTH-like immunoreactivity reduced for at least 3 hours. Chiodera and colleagues (1994), in 8 men against saline, also report lower ACTH. Spaeth-Schwalbe and colleagues (1995), with 5 young men per condition, found ACTH and cortisol responses "almost identical" with DSIP and placebo. Giusti and colleagues (1993), in 8 healthy women, found DSIP "unable to modify" growth hormone or prolactin secretion.
Tested in humans under randomised, controlled conditions.
- Blood hormone levels after an infusion, not sleep or stress outcomes.
- Very small samples. Randomisation is stated only for the 1989 study. Abstracts only.
- Human case reportNo effect found / Low confidence
In 16 people with chronic insomnia, a double-blind, placebo-controlled parallel-group study measured by polysomnography found weak effects on sleep efficiency and sleep latency, partly explainable by a change in the placebo group, and no change in self-rated sleep quality.
Bes and colleagues (1992, Amsterdam) recorded 16 chronic insomniac patients for 5 nights in a sleep laboratory, with DSIP or a glucose placebo before nights 3, 4 and 5. Polysomnography showed "higher sleep efficiency and shorter sleep latency" with DSIP, but the authors call these effects "weak" and say they "in part could be due to an incidental change in the placebo group". Self-rated sleep quality and tiredness did not change. They concluded DSIP is "not likely to be of major therapeutic benefit".
One or a few individual cases. Cannot show whether an effect is general.
- PubMed indexes it as a randomised controlled trial, but the abstract describes a "double-blind matched-pairs parallel-groups design" and never says the allocation was random, so it is graded below an RCT here.
- Three treatment nights in 16 patients. Only the abstract was read.
- Human case reportNo effect found / Very low confidence
In people with insomnia, an independent double-blind placebo-controlled crossover study measured by polysomnography over four nights found that slow-wave (delta) sleep was not modified, and judged the improvement to be of little clinical significance.
Monti and colleagues (1987) recorded insomniac patients by polysomnography. Awakenings, time to fall asleep and waking time fell under DSIP but showed "no significant differences" against baseline or placebo nights. Total and non-REM sleep rose through stage 2, while "slow wave sleep (stages 3 and 4) and rapid-eye-movement sleep were not modified". The authors concluded the improvement "is of little clinical significance".
One or a few individual cases. Cannot show whether an effect is general.
- The abstract does not state how many patients took part or whether the order of treatments was randomised.
- Where DSIP differed from placebo, the same differences already existed at baseline, according to the authors. Only the abstract was read.
- Human case reportSupportive / Very low confidence
In small polysomnography studies of chronic insomnia from the group that discovered DSIP (14 and 18 patients), the authors reported sleep improving to normal values, with no figures in the abstracts and, in one, no control group described.
Schneider-Helmert (1987) studied 14 middle-aged chronic insomniacs over 7 nights under placebo-controlled, double-blind conditions, comparing DSIP nights with placebo nights in the same people, and reports "substantially improved night sleep" and better daytime alertness and performance. A 1986 sleep laboratory study of 18 insomniacs aged 29 to 83 reports that the whole sample "showed normal sleep patterns at the end of the investigation". An open study by Kaeser (1984) in 7 patients with severe insomnia, with no control and no stated measurement method, reports sleep normalised in all but one.
One or a few individual cases. Cannot show whether an effect is general.
- The 1987 study compared placebo and DSIP nights within the same 14 people; no separate placebo group or randomisation is described.
- The 1986 abstract describes no control group. Neither abstract gives numbers.
- These positive reports come from the originating group or a small open study; the independent placebo-controlled studies above were negative or trivial. Abstracts only.
- Human case reportSupportive / Very low confidence
In 6 healthy volunteers given DSIP by morning intravenous infusion, sleep rose by a median of 59% over placebo within a 130-minute daytime window, in a double-blind crossover study from the originating group.
Schneider-Helmert and colleagues (1981), describing "a first study" of DSIP in people, gave it to six normal volunteers (four men, two women) in a double-blind crossover against placebo. They report "sleep increased by 59% (median of total sleep time) within a 130-min interval after the treatment as compared with placebo", measured by behavioural observation and EEG, which they say showed no sedation.
One or a few individual cases. Cannot show whether an effect is general.
- This is the source of the 59% figure seen online: six people, a 130-minute window in the daytime, a median.
- It says nothing about night-time sleep or insomnia. Randomisation is not stated. Only the abstract was read.
- Human case reportMixed / Very low confidence
In 6 middle-aged people with chronic insomnia given a single intravenous dose, the originating group reported longer, less interrupted sleep only in the second hour, with a slight arousing effect in the first.
Schneider-Helmert and Schoenenberger (1981) report "longer sleep duration and a higher quality of sleep with fewer interruptions", but "Sleep-promoting effects occurred only in the second hour after injection, in the first hour a slight arousing effect was indicated."
One or a few individual cases. Cannot show whether an effect is general.
- The abstract does not describe the design or measurement method beyond acute administration. Six patients. Abstract only.
- Human case reportSupportive / Very low confidence
In uncontrolled inpatient series of alcohol and opiate withdrawal (67 and 107 patients), outcomes judged by clinicians were reported as improved in most evaluable patients, after 13% to 27% were excluded from evaluation.
Dick and colleagues (1983) gave DSIP as sole treatment to 67 patients in withdrawal from alcohol (28) or opiates (39); 27% were "lost or unsuitable for evaluation", and a benefit is reported in 48 of the 49 evaluable. A 1984 series of 107 inpatients (47 alcohol, 60 opiate) based assessment on "the clinical evaluation by the physician and the nursing staff"; the abstract says about 13% "from the first" group and 22% "from the second" did not meet the requirements for evaluation, and that symptoms disappeared or improved markedly "in, respectively, 97 and 87% of opiate and alcohol addicts".
One or a few individual cases. Cannot show whether an effect is general.
- Neither abstract describes a control group, placebo or blinding, so improvement cannot be separated from the natural course of withdrawal.
- Outcomes were clinician judgement, not a standard rating scale named in the abstract. The two series may share patients. Abstracts only.
- Animal researchSupportive / Low confidence
In rabbits, DSIP infused into the brain ventricles enhanced delta and spindle EEG patterns; this is the finding the name comes from.
Schoenenberger and Monnier (1977) infused nine synthetic peptides into the brain ventricles of rabbits under double-blind conditions, 58 rabbits including controls. Only the delta sleep-inducing peptide "showed significant and specific enhancement/induction of delta and spindle electroencephalogram patterns".
Observed in animals. Animal results frequently fail to replicate in humans.
- An EEG effect after infusion directly into the brain of rabbits, not a measure of sleep in people.
- Animal researchContradictory / Low confidence
Attempts to repeat the sleep effect in other animals were inconsistent: in rats DSIP did not increase sleep in two studies, and in cats one study found more slow-wave sleep and another less sleep.
Obal and colleagues report that in rats a single injection into the brain ventricles at dark onset "does not promote sleep" (1985) and that DSIP "did not increase sleep" while two synthetic analogues did (1986). In 10 cats given DSIP into the ventricles, Susic and colleagues (1987) found more total and slow-wave sleep. In cats given it into the abdominal cavity and recorded for 10 hours against saline, Sommerfelt (1985) found DSIP "reduced the amount of sleep". A 2006 review calls the sleep-factor hypothesis "extremely poorly documented and still weak".
Observed in animals. Animal results frequently fail to replicate in humans.
- Routes and species differ between studies, which may explain some of the conflict.
- Sample sizes are not given in three of the four abstracts. Results for analogues are not DSIP results.
PMID 3841214PMID 3754970PMID 3620931PMID 3840239PMID 16539679
- Animal researchNo effect found / Very low confidence
In female SHR mice (54 per group), Deltaran, a Russian preparation described as containing DSIP, did not change mean lifespan.
Popovich, Anisimov and colleagues (2003) report that Deltaran "did not influence mean life span", while the last 10% of survivors lived 17.1% longer and total spontaneous tumour incidence was 2.6-fold lower.
Observed in animals. Animal results frequently fail to replicate in humans.
- Deltaran is a product, not plain DSIP; the record does not state its other ingredients or regulatory status.
- One study, from the same network as epitalon's lifespan work, not replicated in sources found. Abstract only.
- Mechanistic reasoningInsufficient evidence / Low confidence
No gene, precursor protein or receptor for DSIP has been identified, according to a 2006 review; a 2011 database analysis proposed related proteins only as putative precursors.
Kovalzon and Strekalova (2006) cite "the lack of isolation of the DSIP gene, protein and possible related receptor". Mikhaleva and colleagues (2011) write that "nothing is known of its protein precursor(s) and their encoding gene(s)" and, from sequence databases, point to a stretch in JMJD1B proteins that differs from DSIP at 2 of 9 positions as a possible precursor of peptides with DSIP-like activity.
A plausible biological explanation, not a measured outcome.
- DSIP-like material has been detected with antibodies, but its identity is uncertain; this is why calling DSIP the body's own sleep hormone goes beyond the evidence.
- The 2011 proposal rests on sequence similarity, not on showing DSIP is made from that protein.
Reported and theoretical risks
- Case reportmild
Small studies reported few side effects, mainly headache
In an uncontrolled series of 107 withdrawal inpatients, tolerance was described as good "aside from headaches reported by a few patients"; a 67-patient series reports "No major side-effect"; a study of 6 healthy volunteers reports none observed. Studies this small and uncontrolled cannot detect uncommon harms.
- Human RCTunknown
Higher heart rate and lower heart rate variability under anaesthesia
In 24 women under general anaesthesia, DSIP significantly increased heart rate and decreased heart rate variability compared with saline. These were physiological measurements, not reported adverse events.
- Mechanismunknown
Immunogenicity and impurities in compounded products
FDA states that compounded drugs containing emideltide "may pose risk for immunogenicity for certain routes of administration" and "may have complexities with regard to peptide-related impurities and API characterization", and that "the agency lacks sufficient information to know whether the drug would cause harm if administered to humans."
- Mechanismunknown
No safety data for the route nominated for compounding
FDA's July 2026 briefing document states: "There are no safety data for emideltide (free base) and emideltide acetate administered by the nominator proposed SC ROA." and "safety for emideltide-related products is insufficiently characterized." Its search of FDA's adverse event database through March 3, 2024 states: "The search retrieved zero reports." No reports is not evidence of safety.
Regulatory status
Status differs by country and changes over time. Each entry is dated and sourced.
USFDAnot approved
FDA's briefing document for the July 2026 Pharmacy Compounding Advisory Committee concludes that "a balancing of the criteria weighs against emideltide (free base and emideltide acetate being placed on that list", the 503A bulks list. It states: "FDA did not identify any data to support the effectiveness of emideltide (free base) or emideltide acetate for the treatment of chronic insomnia, narcolepsy, and opioid withdrawal via the nominated SC ROA." and "There is insufficient evidence to make a conclusion on the effectiveness of IV emideltide for chronic insomnia." It also states: "Emideltide (free base) and emideltide acetate are not registered drugs in any country searched via GlobalEdge."
As of 24 July 2026. Source
USFDAunclear
FDA's Pharmacy Compounding Advisory Committee page lists, for 24 July 2026, "Emideltide (also referred to as delta sleeping inducing peptide (DSIP))-related bulk drug substances", namely emideltide free base and emideltide acetate, for the uses "Opioid withdrawal, chronic insomnia, and narcolepsy". The page, reopened on 6 November 2026, records no vote or outcome.
As of 6 August 2026. Source
USFDA advisory committeeunclear
Second hand: a law firm and a trade journal both report that at its 23-24 July 2026 meeting the committee voted against adding emideltide to the 503A bulks list, 6 in favour and 7 against with one abstention, the only one of the seven peptides reviewed that it did not recommend. Neither report says whether the count covers the free base, the acetate or both. FDA's meeting page, reopened on 6 November 2026, posts no vote record, and FDA has published no decision.
As of 6 November 2026. Source
USHHSunclear
Emideltide is not among the six substances in Appendix A of HHS's enforcement discretion policy, noticed in the Federal Register on 30 October 2026, so that policy does not cover it.
As of 2 November 2026. Source
USFDAunclear
FDA lists "Emideltide (DSIP)" in the table "Bulk drug substances nominated but withdrawn", stating that compounded drugs containing emideltide "may pose risk for immunogenicity for certain routes of administration" and that "FDA has not identified safety-related information regarding emideltide for the proposed route of administration."
As of 22 April 2026. Source
USFDAunclear
FDA's 503A bulk drug substance categories list updated on 14 May 2026 has no entry for emideltide or DSIP in any category.
As of 14 May 2026. Source
Research and analysis
Sources
- 1. Bes F et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992. PubMed 1299794
- 2. Monti JM et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International Journal of Clinical Pharmacology Research. 1987. PubMed 3583493
- 3. Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. European Neurology. 1987. PubMed 3622582
- 4. Schneider-Helmert D. Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. European Neurology. 1986. PubMed 3792404
- 5. Kaeser HE. A clinical trial with DSIP. European Neurology. 1984. PubMed 6391926
- 6. Schneider-Helmert D. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. International Journal of Clinical Pharmacology, Therapy, and Toxicology. 1981. PubMed 6895513
- 7. Schneider-Helmert D. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981. PubMed 7028502
- 8. Pomfrett CJ et al. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. European Journal of Anaesthesiology. 2009. PubMed 19142086
- 9. Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology. 1983. PubMed 6328354
- 10. Dick P et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. European Neurology. 1984. PubMed 6548969
- 11. Bjartell A et al. Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology. 1989. PubMed 2554357
- 12. Chiodera P et al. Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men. Hormone Research. 1994. PubMed 7698722
- 13. Späth-Schwalbe E et al. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology. 1995. PubMed 7777652
- 14. Giusti M et al. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Psychoneuroendocrinology. 1993. PubMed 8475226
- 15. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences of the USA. 1977. PubMed 265572(open access)
- 16. Obál F Jr et al. Effects of intracerebroventricular injection of delta sleep-inducing peptide (DSIP) and an analogue on sleep and brain temperature in rats at night. Pharmacology Biochemistry and Behavior. 1985. PubMed 3841214
- 17. Obál F Jr et al. Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep. Pharmacology Biochemistry and Behavior. 1986. PubMed 3754970
- 18. Sušić V, Masirević G, Totić S. The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat. Brain Research. 1987. PubMed 3620931
- 19. Sommerfelt L. Reduced sleep in cats after intraperitoneal injection of delta-sleep-inducing peptide (DSIP). Neuroscience Letters. 1985. PubMed 3840239
- 20. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006. PubMed 16539679
- 21. Mikhaleva II et al. JmjC-domain-containing histone demethylases of the JMJD1B type as putative precursors of endogenous DSIP. Peptides. 2011. PubMed 21262293
- 22. Popovich IG et al. Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mechanisms of Ageing and Development. 2003. PubMed 12782416
- 23. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)
- 24. FDA Briefing Document for Emideltide-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 25. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026. View source(open access)
- 26. Crossan SS, Watkins S. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight Alert. 2026. View source(open access)
- 27. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. U.S. Department of Health and Human Services. 2026. View source(open access)
- 28. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026. View source(open access)